{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:40:30Z","timestamp":1787586030673,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Epidermolysis bullosa (EB) is a genodermatosis, characterized by the formation of extended blisters and lesions on the skin and mucous membranes upon minimal mechanical trauma. The disease is caused by mutations in genes encoding proteins that are essential for skin stability. Functional impairment, reduction, or absence of one of these proteins results in skin fragility due to reduced connectivity between dermis and epidermis. Currently, gene therapy represents the only treatment option with the potential to cure this severe blistering skin disease. Two promising forms of gene therapy are potentially feasible for EB: gene replacement and genome editing. While genome editing for genodermatoses remains at the preclinical stage, gene replacement approaches are clinically advanced and have been applied already to a small number of patients with junctional and dystrophic forms of EB. Here, the viral transduction of the \u201cwild-type\u201d transgene into skin stem cells, followed by autologous grafting of corrected epidermal sheets, led to the regeneration of stable skin. Recent developments regarding designer nuclease-based gene editing strategies enable the establishment of alternative options to restore the gene function in genodermatoses. This is particularly true in cases wherein genetic constellation hinders gene therapy-based gene replacement.<\/jats:p>","DOI":"10.3389\/fgene.2021.658295","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T07:58:56Z","timestamp":1619769536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Gene Replacement Therapies for Genodermatoses: A Status Quo"],"prefix":"10.3389","volume":"12","author":[{"given":"Ulrich","family":"Koller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.omtm.2017.06.008","article-title":"Traceless targeting and isolation of gene- edited immortalized keratinocytes from epidermolysis bullosa simplex patients.","volume":"6","author":"Aushev","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","article-title":"Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells.","volume":"137","author":"Bauer","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","article-title":"CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient.","volume":"26","author":"Benati","year":"2018","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","article-title":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-mediated gene editing.","volume":"27","author":"Bonafont","year":"2019","journal-title":"Mol. Ther."},{"key":"B6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nsmb.1550","article-title":"Nonsense-mediated mRNA decay (n.d.) mechanisms.","volume":"16","author":"Brogna","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nrmicro1263","article-title":"Genome-wide analysis of retroviral DNA integration.","volume":"3","author":"Bushman","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia.","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.19","article-title":"Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes.","volume":"5","author":"Chamorro","year":"2016","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"B10","first-page":"130","article-title":"DNA double strand break repair via non-homologous end-joining.","volume":"2","author":"Davis","year":"2013","journal-title":"Transl. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa.","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem. Cell Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.celrep.2019.04.055","article-title":"Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa.","volume":"27","author":"De Rosa","year":"2019","journal-title":"Cell Rep."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078678","article-title":"Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALEN.","volume":"8","author":"Dupuy","year":"2013","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.","volume":"70","author":"Fine","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjd.18559","article-title":"EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa.","volume":"182","author":"Gaucher","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/jid.2015.364","article-title":"Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore achnoring fibrils in RDEB.","volume":"136","author":"Georgiadis","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa.","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility.","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells.","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jid.2015.11.028","article-title":"Meganuclease-mediated COL7A1 gene correction for recessive dystrophic epidermolysis bullosa.","volume":"136","author":"Izmiryan","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair.","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-corrected fibroblast therapy for recessive dystrophic epiermolysis bullosa using a self-inactivating COL7A1 retroviral vector.","volume":"136","author":"Jack\u00f3w","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","article-title":"Predictable CRISPR\/Cas9-mediated COL7A1 reframing for dystrophic epidermolysis bullosa.","volume":"140","author":"Kocher","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","article-title":"Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases.","volume":"25","author":"Kocher","year":"2017","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","article-title":"Improved double-nicking strategies for COL7A1 editing by homologous recombination.","volume":"18","author":"Kocher","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.omtn.2018.05.005","article-title":"CRISPR\/Cas9-mediated treatment ameliorates the phenotype of the epidermolytic palmoplantar keratoderma-like mouse.","volume":"12","author":"Luan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010112","article-title":"Context-dependent strategies for enhanced genome editing of genodermatoses.","volume":"9","author":"March","year":"2020","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.jid.2019.03.1146","article-title":"Gene editing-mediated disruption of epidermolytic ichthyosis-associated KRT10 alleles restores filament stability in keratinocytes.","volume":"139","author":"March","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1113\/ep086044","article-title":"Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders.","volume":"103","author":"March","year":"2018","journal-title":"Exp. Physiol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","article-title":"Gene therapy for epidermolysis bullosa.","volume":"139","author":"Marinkovich","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"B37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","article-title":"Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells.","volume":"11","author":"Mencia","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B39","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/sj.gt.3302832","article-title":"Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease.","volume":"13","author":"M\u00fchle","year":"2006","journal-title":"Gene Ther."},{"key":"B40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2302\/kjm.2014-0013-RE","article-title":"Advances in gene\/cell therapy in epidermolysis bullosa.","volume":"64","author":"Murauer","year":"2015","journal-title":"Keio. J. Med."},{"key":"B41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI200317193","article-title":"Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.","volume":"111","author":"Ortiz-Urda","year":"2003","journal-title":"J. Clin. Invest."},{"key":"B42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa.","volume":"17","author":"Remington","year":"2009","journal-title":"Mol. Ther."},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.","volume":"6","author":"Sebastiano","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B44","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa.","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1089\/hum.2010.023","article-title":"Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue.","volume":"21","author":"Siprashvili","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"B46","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa.","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR\/Cas9.","volume":"139","author":"Takashima","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"B48","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1038\/jid.2009.131","article-title":"Recessive epidermolytic hyperkeratosis caused by a previously unreported termination codon mutation in the keratin 10 gene.","volume":"129","author":"Terheyden","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"B49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.","volume":"18","author":"Titeux","year":"2010","journal-title":"Mol. Ther."},{"key":"B50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.","volume":"363","author":"Wagner","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.","volume":"1","author":"Webber","year":"2016","journal-title":"NPJ Regen. Med."},{"key":"B52","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.","volume":"128","author":"Wong","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.mt.6300041","article-title":"Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing.","volume":"15","author":"Woodley","year":"2007","journal-title":"Mol. Ther."},{"key":"B54","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa.","volume":"133","author":"Woodley","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"B55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/cr.2017.76","article-title":"Homology-mediated end joining-based targeted integration using CRISPR\/Cas9.","volume":"27","author":"Yao","year":"2017","journal-title":"Cell Res."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.658295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T07:59:18Z","timestamp":1619769558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.658295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":55,"alternative-id":["10.3389\/fgene.2021.658295"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.658295","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"article-number":"658295"}}